Ciltacabtagene autoleucel vs Zevorcabtagene autoleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Ciltacabtagene autoleucel

Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation

Approved in Multiple MyelomaCAR-T (autologous cellular therapy)
Partial signal

NCT04181827 · Phase 3 · active, not recruiting

This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.

Next expected readout: February 2027 · NCT04133636 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)

Result source: NCT04181827

Zevorcabtagene autoleucel

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 1/2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03975907 · Phase 1/2 · status unknown

This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).

Reported efficacy

Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)

Result source: NCT03975907

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCiltacabtagene autoleucelZevorcabtagene autoleucel
PFS, median—Trial running · NCT05257083—Not reported
OS, median27.0bn 8NCT03548207—Not reported
ORR97.1%bn 68NCT03548207
2 other results
—Not reported
VGPR or better96.6%bn 29NCT03548207
2 other results
—Not reported
MRD negativity100%bn 18NCT03548207
2 other results
—Not reported

PFS, median

Ciltacabtagene autoleucel
—Trial running · NCT05257083
Zevorcabtagene autoleucel
—Not reported

OS, median

Ciltacabtagene autoleucel
27.0bn 8NCT03548207
Zevorcabtagene autoleucel
—Not reported

ORR

Ciltacabtagene autoleucel
97.1%bn 68NCT03548207
2 other results
Zevorcabtagene autoleucel
—Not reported

VGPR or better

Ciltacabtagene autoleucel
96.6%bn 29NCT03548207
2 other results
Zevorcabtagene autoleucel
—Not reported

MRD negativity

Ciltacabtagene autoleucel
100%bn 18NCT03548207
2 other results
Zevorcabtagene autoleucel
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zevorcabtagene autoleucel
LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). NCT03975907 · Phase 1/2 · design grade: weak · publication or press release
LUMMICAR STUDY 2 (NCT03915184): objective response rate 100% in evaluable relapsed/refractory multiple myeloma patients. NCT03915184 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ciltacabtagene autoleucel: 2 of 4 rows · Zevorcabtagene autoleucel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCiltacabtagene autoleucel
Dropout rate
n/a: no completion milestonea
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
n/a: no completion milestonePhase 1b (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (Japan Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestone
NCT05347485 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
—Phase 1b (US Population)
NCT03548207 · Phase 1/2
—Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
—Phase 2 (US Population)
NCT03548207 · Phase 1/2
—
NCT05347485 · Phase 2 · registry result, not featured evidence
Serious AEs
47.1%a
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
37.9%Phase 1b (US Population)
NCT03548207 · Phase 1/2
11.1%Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
61.8%Phase 2 (US Population)
NCT03548207 · Phase 1/2
51.2%
NCT05347485 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
neutropenia 89.9%
cytokine release syndrome 62%
thrombocytopenia 54.3%
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
neutropenia 100%
cytokine release syndrome 89.7%
thrombocytopenia 86.2%
NCT03548207 · Phase 1/2
neutropenia 88.9%
cytokine release syndrome 77.8%
thrombocytopenia 77.8%
NCT03548207 · Phase 1/2
neutropenia 94.1%
cytokine release syndrome 86.8%
anaemia 83.8%
NCT03548207 · Phase 1/2
neutropenia 80.5%
anaemia 59.8%
cytokine release syndrome 57.3%
NCT05347485 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ciltacabtagene autoleucel

PFS NA vs 11.79 PVd or DPd months
time to event · months
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
ORR 97.1% (n=68)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
100% (n=8)
NCT03548207 · Phase 1/2
57.3% (n=82)
NCT05347485 · Phase 2 · registry result, not featured evidence
VGPR or Better 96.6% (n=29)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
94.1% (n=68)
NCT03548207 · Phase 1/2
100% (n=8)
NCT03548207 · Phase 1/2
MRD Negative 100% (n=18)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
89.7% (n=39)
NCT03548207 · Phase 1/2
75% (n=8)
NCT03548207 · Phase 1/2
Clinical Benefit 100% (n=29)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 3 more results
97.1% (n=68)
NCT03548207 · Phase 1/2
100% (n=9)
NCT03548207 · Phase 1/2
59.8% (n=82)
NCT05347485 · Phase 2 · registry result, not featured evidence
Duration of Response NA months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 3 more results
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
NA months
NCT05347485 · Phase 2 · registry result, not featured evidence
Time to First Response 0.95 months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
0.95 months
NCT03548207 · Phase 1/2
0.92 months
NCT03548207 · Phase 1/2
PFS NA months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 3 more results
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
NA months
NCT05347485 · Phase 2 · registry result, not featured evidence
Overall Survival NA months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 3 more results
NA months
NCT03548207 · Phase 1/2
27.04 months
NCT03548207 · Phase 1/2
NA months
NCT05347485 · Phase 2 · registry result, not featured evidence
EQ-5D-5L Utility -0.1 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0 score @ 4wk
NCT03548207 · Phase 1/2
0 score @ 8wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 26.29wk
NCT03548207 · Phase 1/2
0.1 score @ 30.29wk
NCT03548207 · Phase 1/2
0.1 score @ 34.29wk
NCT03548207 · Phase 1/2
0.1 score @ 38.29wk
NCT03548207 · Phase 1/2
0.1 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
0.1 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.1 score @ 54.29wk
NCT03548207 · Phase 1/2
-0.05 score @ 1wk
NCT03548207 · Phase 1/2
-0.06 score @ 4wk
NCT03548207 · Phase 1/2
-0.03 score @ 8wk
NCT03548207 · Phase 1/2
0.01 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.04 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.02 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.01 score @ 26.29wk
NCT03548207 · Phase 1/2
0.04 score @ 30.29wk
NCT03548207 · Phase 1/2
0.05 score @ 34.29wk
NCT03548207 · Phase 1/2
0.07 score @ 38.29wk
NCT03548207 · Phase 1/2
0.04 score @ 42.29wk
NCT03548207 · Phase 1/2
0.14 score @ 46.29wk
NCT03548207 · Phase 1/2
EQ-5D-5L VAS -6.7 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.6 score @ 4wk
NCT03548207 · Phase 1/2
2.2 score @ 8wk
NCT03548207 · Phase 1/2
5.3 score @ 11.14wk
NCT03548207 · Phase 1/2
1.9 score @ 14.29wk
NCT03548207 · Phase 1/2
6.4 score @ 18.29wk
NCT03548207 · Phase 1/2
4.8 score @ 22.29wk
NCT03548207 · Phase 1/2
6.1 score @ 26.29wk
NCT03548207 · Phase 1/2
9.6 score @ 30.29wk
NCT03548207 · Phase 1/2
11 score @ 34.29wk
NCT03548207 · Phase 1/2
7.2 score @ 38.29wk
NCT03548207 · Phase 1/2
10 score @ 42.29wk
NCT03548207 · Phase 1/2
11.9 score @ 46.29wk
NCT03548207 · Phase 1/2
10.2 score @ 50.29wk
NCT03548207 · Phase 1/2
-2 score @ 54.29wk
NCT03548207 · Phase 1/2
-13.75 score @ 1wk
NCT03548207 · Phase 1/2
-0.75 score @ 4wk
NCT03548207 · Phase 1/2
-4.5 score @ 8wk
NCT03548207 · Phase 1/2
-3 score @ 11.14wk
NCT03548207 · Phase 1/2
-1.88 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.25 score @ 26.29wk
NCT03548207 · Phase 1/2
2.5 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-2.5 score @ 38.29wk
NCT03548207 · Phase 1/2
-12.5 score @ 42.29wk
NCT03548207 · Phase 1/2
-10 score @ 46.29wk
NCT03548207 · Phase 1/2
PGI-S -0.3 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.3 score @ 1wk
NCT03548207 · Phase 1/2
-0.3 score @ 4wk
NCT03548207 · Phase 1/2
-0.1 score @ 4wk
NCT03548207 · Phase 1/2
-0.3 score @ 8wk
NCT03548207 · Phase 1/2
0.3 score @ 8wk
NCT03548207 · Phase 1/2
-0.3 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.3 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.4 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 30.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 34.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 38.29wk
NCT03548207 · Phase 1/2
0 score @ 38.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 42.29wk
NCT03548207 · Phase 1/2
-0.6 score @ 46.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
-0.9 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 54.29wk
NCT03548207 · Phase 1/2

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Zevorcabtagene autoleucel's landscape